Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Store-operated calcium entry channel protein (Orai1) (Orai1)
- Target
- Orai1
- Molecular classification
- Ion channel, Calcium channel, Store-operated channel
01
Overview
The **store-operated calcium entry channel protein** commonly refers to Orai1, an integral plasma membrane protein that forms the pore of Calcium release-activated calcium (CRAC) channels, mediating store-operated calcium entry (SOCE) into cells. Orai1 is activated when depletion of endoplasmic reticulum (ER) Ca²⁺ stores is sensed by ER-resident proteins named STIM1 and STIM2. Upon store depletion, STIM proteins undergo conformational change and translocate to ER–plasma membrane junctions, where they physically interact with Orai1, triggering channel opening and allowing extracellular calcium influx. This mechanism is essential for diverse biological processes including signal transduction, gene expression, immune cell activation, and maintenance of cellular calcium homeostasis. Orai1 dysfunction is implicated in immunodeficiency, muscle disorders, and neurological diseases. Targeting the Orai1 channel and SOCE pathway is under investigation for immunomodulation and treatment of pathological calcium signaling in various diseases[1][2][3][5][6].
- Other names
- Store-operated calcium channelCalcium release-activated calcium channel protein 1CRACM1CRAC channel proteinOrai calcium channel protein 1Store-operated calcium entry protein 1
02
Mechanism of action
Inhibition of Orai1-mediated calcium entry, reducing downstream calcium-dependent cellular processes; Modulation of immune cell activation by limiting calcium influx
03
Biological functions
Calcium signalingCalcium homeostasisGene transcription regulationImmune responseCell metabolismCell motility
04
Disease associations
Immunodeficiency (e.g., severe combined immunodeficiency-like disorders)Myopathies (e.g., tubular aggregate myopathy)Syndromic diseases (e.g., Stormorken syndrome)Neurological disordersInflammation
05
Safety considerations
Immunosuppression and increased risk of infection from broad SOCE inhibitionPossible interference with normal neuronal and muscular function
06
Interacting drugs
BTP2 (YM-58483, a research inhibitor)
2 more in the full profile.
07
Biomarkers
Orai1 protein expression (for functional SOCE)STIM1/STIM2 expression (regulatory partners)
Beyond the preview
Go deeper on Store-operated calcium entry channel protein (Orai1) (Orai1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Store-operated calcium entry channel protein (Orai1) (Orai1).